Reformulation of a new vancomycin analog: An example of the importance of buffer species and strength

AAPS PharmSciTech

Volumn 7, Issue 1, 2006, Pages

  Johnson, Jennifer L H ^a   Yalkowsky, Samuel H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Blood surrogate; Buffer species; In vitro model; pH; Phlebitis; Precipitation; Prediction; Probability; Sensitivity; Solubility; Specificity

Indexed keywords

ACETIC ACID; BUFFER; NEW DRUG; PHOSPHATE; VAN AN; VANCOMYCIN DERIVATIVE;

ANALYTIC METHOD; ARTICLE; BLOOD PH; CONTROLLED STUDY; DILUTION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SCREENING; FLOW RATE; INJECTION; MEDICAL INSTRUMENTATION; PH MEASUREMENT; PHLEBITIS; PKA; PRECIPITATION; REPRODUCIBILITY; SPECTROPHOTOMETER; STRENGTH; VALIDATION STUDY;

EID: 30944448889     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070105     Document Type: Article

References (19)

1. Hadaway L, Chamallas SN. Vancomycin. J Infus Nurs. 2003;26:278-284. PubMed DOI:10.1097/00129804-200309000-00003
2. Takács-Novák K, Noszál B, Tokes-Kovesdi M, Szasz G. Acid base properties and proton-speciation of vancomycin. Int J Pharm. 1993;89:261-263. DOI:10.1016/0378-5173(93)90252-B
3. Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem. 2001;8:1759-1773. PubMed
4. Salaria M. Teicoplanin, Indian Pediatr. 2001;38:372-375. PubMed
5. Douchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. Clin Microbiol Infect. 2004;10:275.
6. Douchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. Clin Microbiol infect. 2004;10:276.
7. Internet press release from Biospace Beat, Biotechnology and Pharmaceutical News, Available at: http://www.biospace.com/ news_story.cfm?StoryID=14456320&full=1. Accessed December 28, 2004.
8. Targocid for Injection package insert. Available at: http://home.intekom.com/pharm/roussel/targocid.html. Accessed December 28, 2004.
9. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs. 2004;64:913-936. PubMed
10. Taxis K, Barber N. Ethnographic study of incidence and severity of intravenous drug errors. BMJ. 2003;326:1-4. DOI:10.1136/bmj326.7391.684
11. Lanbeck P, Odenholt I, Paulsen O. Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study. Scand J Infect Dis. 2002;34:512-519. PubMed DOI:10.1080/00365540110080908
12. Johnson JLH, He Y, Yalkowsky SH. Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J Pharm Sci, 2003;92:1574-1581. PubMed DOI:10.1002/jps.10396
13. Rowland M, Tozer TM. Clinical Pharmacokinetics: Concepts and Applications. Baltimore, MD: Lippincott Williams & Wilkins; 1995:138.
14. Abbott Laboratories NDA no. 13-025/S-035 submission. Available at: http://www.fda.gov/oder/ogd/rid/13025S35.pdf. Accessed November 18, 2004.
15. Surakitbanharn Y, Simamora P, Ward GH, Yalkowsky SH. Precipitation of pH solubilized phenytoin. Int J Pharm. 1994;109:27-33. DOI:10.1016/ 0378-5173(04)90118-X
16. Davio SR, McShane MM, Kaluk TJ, Zaya RM, Cole SL. Precipitation of the renin inhibitor ditekiren upon i.v. infusion: in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharm Res. 1991;8:80-83. PubMed DOI:10.1023/A:101588642586
17. Greenfield JC, Loux SJ, Sood VK, Jenkins KM, Davio SR. In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel renin inhibitor pseudopeptide. Pharm Res. 1991;8:475-479. PubMed DOI:10.1023/A:1015847027254
18. Faulding Pharmaceuticals. Editorial: vancomycin injection. Pharm J. 1999;263:880. PubMed
19. Kastango ES, Hadaway L. New perspectives on vancomycin use in home care, part 2: delivery systems. Int J Pharm Comp. 2002;6:55-57. PubMed